Insider · CIK 0001816207
Matthew Call
Files at ITOS (iTeos Therapeutics, Inc.). First filing -, latest -.
In brief
Matthew Call files SEC Form 4 as COO at ITOS (iTeos Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Matthew Call has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | UTender of shares Common Stock | -161,898 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,063 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -135,937 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -41,694 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -66,170 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,074 | - | - | 0 | Aug 29, 2025 |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -146,835 | - | - | 0 | Aug 29, 2025 |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 161,898 | Mar 11, 2025 |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +145,000 | $0.00 | $0 | 145,000 | Mar 11, 2025 |
Questions about Matthew Call
Answered from the filings on this page, as of the latest one.
Is Matthew Call buying or selling?
Matthew Call has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Matthew Call's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew Call has 0.
Where does Matthew Call file Form 4?
Matthew Call has filed Form 4 at ITOS (iTeos Therapeutics, Inc.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.